Skip to main content

Ureteropelvic Junction Obstruction

Ureteropelvic junction obstruction (UPJO) is a functionally significant impairment of urine flow from the renal pelvis into the proximal ureter that, untreated, leads to progressive hydronephrosis, parenchymal loss, recurrent pyelonephritis, and stone formation.[1][2] It is the most common cause of congenital obstructive uropathy (incidence ~0.5–1 per 1,000 births, unilateral in 60–80%, left side and males predominate) and the prototype upper-tract reconstruction problem for the urologic surgeon — pyeloplasty success rates above 95% define the benchmark against which all other ureteral reconstructions are measured.[3][7]

Classification​

UPJO is split first by timing, then by mechanism:[1][3]

  • Primary (congenital) — intrinsic developmental abnormality, typically diagnosed antenatally or in childhood
  • Secondary (acquired) — develops later from stones, prior endoscopic or open surgery, ischemic or radiation stricture, malignancy, retroperitoneal fibrosis, or endometriosis
MechanismPathologyExamples
Mural (intrinsic)Aperistaltic UPJ segment from abnormal smooth muscle, increased collagen, and disordered innervation; failure of complete recanalization in developmentAdynamic segment — most common cause
Intramural (intraluminal)Obstruction within the lumenFibroepithelial polyp, impacted stone
Extramural (extrinsic)External compression, often intermittentLower-pole crossing vessel, kinks, fibrous bands, high ureteral insertion, malrotated or fused kidney

A lower-pole crossing vessel is identified in roughly 30–60% of adults with UPJO and changes the operation — it contraindicates endopyelotomy and mandates anterior ureteral transposition at pyeloplasty.[14][17]

Pathophysiology​

The dominant lesion in primary UPJO is functional, not anatomic: an aperistaltic segment fails to propagate the peristaltic wave, so the renal pelvis cannot eject its bolus despite a grossly patent lumen.[5] Histology shows smooth-muscle disarray, increased collagen deposition, and stroma-like cells at the obstructing segment; activated Hedgehog–Gli signaling has been implicated in the developmental defect.[4]

The clinical course reflects the renal pelvis acting first as a hydraulic buffer and then as a failed one:[5]

  1. Compensated phase — the compliant pelvis dilates and damps intrapelvic pressure, sparing parenchyma
  2. Decompensated phase — sustained tubular stretch drives interstitial inflammation, myofibroblast activation, tubulointerstitial fibrosis, and tubular apoptosis, with progressive loss of differential function

For the reconstructive surgeon, the operative implication is simple: timing matters. Pyeloplasty arrests deterioration in essentially every case and improves function in most, with the largest gains in kidneys with the most depressed preoperative split function — provided the parenchyma has not already been replaced by fibrosis.[19]

Clinical Presentation​

Pediatric​

Most cases are now identified on prenatal or neonatal ultrasound for antenatal hydronephrosis, which is detected in up to 4.5% of pregnancies.[3][7] Postnatal symptoms when present include flank or abdominal pain, palpable mass in the neonate, febrile UTI, hematuria, and failure to thrive.

Adult​

In adults UPJO is typically symptomatic or detected incidentally on imaging for unrelated complaints:[1][2]

  • Flank pain — the classic presentation; often intermittent, exacerbated by diuresis (high fluid intake, alcohol, caffeine — "Dietl's crisis")
  • Recurrent pyelonephritis from urinary stasis
  • Stone formation — both a presenting sign and a downstream complication
  • Hematuria (gross or microscopic)
  • Renal insufficiency when bilateral or in a solitary kidney
  • Asymptomatic hydronephrosis found on cross-sectional imaging for an unrelated indication

A non-trivial fraction of adult UPJO is silent until decompensation — preserve a low threshold for functional imaging when hydronephrosis is found incidentally.[6]

Diagnostic Evaluation​

The reconstructive workup pairs anatomic imaging (to identify crossing vessels, stones, malrotation, and the level of obstruction) with functional imaging (to confirm true obstruction and quantify split function).[2][6][9]

ModalityRoleStrengthsLimitations
Renal ultrasoundFirst-line screen; quantify hydronephrosis (SFU grade or UTD score)Non-invasive, no radiationNo functional or anatomic detail beyond dilation
CT urographyAnatomic gold standard in adultsCrossing vessels, stones, malrotation, parenchymal thicknessRadiation; no function
MR urographyAnatomic + some functional data; preferred in children and pregnancyNo radiation; soft-tissue detailAvailability, cost, scan time
Diuretic renography (Tc-99m MAG3)Functional gold standardQuantifies drainage and split functionRadiation; needs adequate hydration and bladder drainage
Retrograde pyelogramMaps stricture length and confirms anatomy at the time of interventionDirect anatomic detailInvasive; usually combined with the operation itself
Whitaker testDirect pressure–flow measurement when renography is equivocalResolves the equivocal caseInvasive; rarely needed in modern practice

Diuretic renography​

MAG3 (preferred) or DTPA is administered intravenously; furosemide is given to provoke diuresis once the collecting system is filled. Time–activity curves yield two outputs that drive operative decision-making:[2]

  • T½ of drainage — <10 min normal, 10–20 min equivocal, >20 min obstructive
  • Differential renal function — >10% loss of split function (or interval drop on serial scans) is a classic operative trigger

Pediatric grading — UTD classification​

The 2014 multidisciplinary Urinary Tract Dilation (UTD) consensus replaced the older SFU grading with a unified pre- and postnatal score based on anteroposterior renal pelvis diameter, calyceal dilation, parenchymal thickness, parenchymal appearance, ureter, and bladder findings.[10][11] APRPD is the strongest single predictor of needing intervention, with reported cutoffs of 16–24 mm; high-grade hydronephrosis (SFU 3–4 / UTD P3) progresses to surgery in roughly one-third of patients managed conservatively.[7]

Management​

Indications for intervention​

Surgery is indicated for:[1][2][10]

  • Symptomatic obstruction (pain, recurrent infection)
  • >10% loss of differential renal function or interval decline on serial renograms
  • Progressive hydronephrosis
  • Stone formation in the obstructed system
  • Pyelonephritis attributable to obstruction

Active surveillance​

Asymptomatic adults with stable function can be safely surveilled. In a representative series of 21 adults followed at 6–12 month intervals with renography, 71% remained on surveillance at a mean of 48 months, and 29% crossed over to surgery at an average of 34 months — almost always for symptom progression rather than functional loss.[12]

Surgical options​

ProcedureSuccess rateBest fitCaveats
Open dismembered (Anderson–Hynes) pyeloplasty>95%Historic gold standard; redo pyeloplasty, complex anatomyLarger incision; longer recovery
Laparoscopic pyeloplasty>90%Centers without robotic accessSteep learning curve; longer operative time
Robot-assisted laparoscopic pyeloplasty (RALP)90–97%Current standard of care in adults and children >6 mo / >15 cm pubis-to-xiphoidCost; equipment availability
Endopyelotomy (antegrade or retrograde)42–90%Short intrinsic stenosis without crossing vessel; salvage after failed pyeloplastyInferior to pyeloplasty; contraindicated with crossing vessel, long stricture, severe hydronephrosis, or poor function

Pyeloplasty technique​

The Anderson–Hynes dismembered pyeloplasty is the reference operation and works for essentially every UPJO anatomy:[13][14]

  1. Expose the UPJ (transperitoneal or retroperitoneal; open, laparoscopic, or robotic)
  2. Identify and preserve any crossing vessel
  3. Excise the diseased aperistaltic segment
  4. Spatulate the proximal ureter laterally for ~1.5–2 cm
  5. Reduce the redundant pelvis if needed
  6. Construct a tension-free, watertight, dependent anastomosis over a JJ stent (typically 4–6 weeks)
  7. Anterior ureteral transposition when a lower-pole vessel is present

Non-dismembered alternatives are reserved for specific anatomy and rarely used today:[14]

  • Foley Y-V plasty — high ureteral insertion with a dependent pelvis
  • Fenger plasty — short stricture, Heineke–Mikulicz principle
  • Culp–DeWeerd or Scardino flap — long strictures with a generous pelvis

Endopyelotomy​

Antegrade or retrograde incision of the stenotic segment through a single full-thickness cut, stented for 4–6 weeks. Long-term failure rates substantially exceed pyeloplasty (adjusted hazard ratio for treatment failure ≈ 1.78 vs minimally invasive pyeloplasty), and the procedure is contraindicated with a crossing vessel, stricture >2 cm, high-grade hydronephrosis, or split function <25%.[14][17][18]

Comparative outcomes​

A systematic review and meta-analysis of robot-assisted vs laparoscopic vs open pyeloplasty showed equivalent success and complication rates across approaches, with shorter hospital stay favoring minimally invasive surgery in adults.[13] A 2023 network meta-analysis ranked transperitoneal RALP as the highest-performing minimally invasive approach.[15] A single-institution series of 168 RALPs reported a 96.9% success rate with 8-year failure-free survival of 91.5%, and a comparative-effectiveness analysis confirmed endopyelotomy as the inferior option (15% failure vs 7% MIS pyeloplasty vs 9% open).[16][18]

Pediatric considerations​

Most antenatally detected hydronephrosis resolves spontaneously; only a minority requires surgery.[3][7] Key operative thresholds for the pediatric reconstructive surgeon:

  • Open pyeloplasty remains common in young infants but is no longer mandatory
  • Robotic pyeloplasty is feasible once pubis-to-xiphoid distance exceeds ~15 cm — typically by 6 months of age in full-term infants — with success and complication rates equivalent to open and shorter hospital stays[7]
  • Indications mirror adult practice: declining split function, recurrent infection, symptoms, or progressive UTD/SFU grade

Urinary biomarker panels (NGAL, KIM-1, MCP-1, and broader urinary proteomic screens) have been proposed to predict which equivocal cases will progress, but none is yet clinical-grade.[7]

Special situations​

Crossing vessel​

A lower-pole vessel is the single most important anatomic finding to identify preoperatively — it dictates the operation. Either CT angiography or intraoperative inspection identifies it; dismembered pyeloplasty with anterior transposition is standard. Pure vascular hitch (Hellström-style transposition without dismemberment) risks leaving an undiagnosed intrinsic component and is generally avoided in adults.[14][17]

Failed pyeloplasty​

Redo pyeloplasty — increasingly performed robotically — is safe and outperforms open salvage in modern series. Endopyelotomy is a reasonable salvage option for short recurrent strictures without a crossing vessel; longer redo strictures generally need formal redo dismembered pyeloplasty, ureterocalicostomy (for an intrarenal pelvis with adequate lower-pole parenchymal thinning), or buccal mucosa onlay ureteroplasty.[13]

Anatomic anomalies​

UPJO is over-represented in horseshoe and malrotated kidneys; aberrant rotation or fusion alters the location of the crossing vessel and the dependent point of the pelvis, and dismembered pyeloplasty must be tailored accordingly.[8]

Outcomes​

Pyeloplasty arrests functional deterioration in almost every case and improves split function in the majority — with the largest gains in the kidneys whose preoperative function was most depressed. Drainage on diuretic renography normalizes in roughly 85% of patients postoperatively.[19] Long-term durability is excellent: in a representative RALP cohort, 8-year failure-free survival was 91.5% (96.3% for stented procedures), with the bulk of failures occurring in the first 24 months.[16]

References​

1. Rai A, Hsieh A, Smith A. "Contemporary diagnosis and management of pelvi-ureteric junction obstruction." BJU Int. 2022;130(3):285–290. doi:10.1111/bju.15689

2. Khan F, Ahmed K, Lee N, et al. "Management of ureteropelvic junction obstruction in adults." Nat Rev Urol. 2014;11(11):629–638. doi:10.1038/nrurol.2014.240

3. Weitz M, Portz S, Laube GF, Meerpohl JJ, Bassler D. "Surgery versus non-surgical management for unilateral ureteric-pelvic junction obstruction in newborns and infants less than two years of age." Cochrane Database Syst Rev. 2016;7:CD010716. doi:10.1002/14651858.CD010716.pub2

4. Sheybani-Deloui S, Chi L, Staite MV, et al. "Activated Hedgehog-Gli signaling causes congenital ureteropelvic junction obstruction." J Am Soc Nephrol. 2018;29(2):532–544. doi:10.1681/ASN.2017050482

5. Alberti C. "Congenital ureteropelvic junction obstruction: physiopathology, decoupling of tout court pelvic dilatation-obstruction semantic connection, biomarkers to predict renal damage evolution." Eur Rev Med Pharmacol Sci. 2012;16(2):213–219.

6. Whitworth P, Courtney KG, Oto A, et al. "ACR Appropriateness Criteria® Hydronephrosis on prior imaging — unknown cause." J Am Coll Radiol. 2024;21(6S):S144–S167. doi:10.1016/j.jacr.2024.02.020

7. Diamond DA, Chan IHY, Holland AJA, et al. "Advances in paediatric urology." Lancet. 2017;390(10099):1061–1071. doi:10.1016/S0140-6736(17)32282-1

8. Meshaka R, Biassoni L, Leung G, Mushtaq I, Hiorns MP. "Radiological and surgical correlation of pelviureteric junction obstruction in positional anomalies of the kidney in children." Pediatr Radiol. 2023;53(3):544–557. doi:10.1007/s00247-022-05557-7

9. Wolf JS, Siegel CL, Brink JA, Clayman RV. "Imaging for ureteropelvic junction obstruction in adults." J Endourol. 1996;10(2):93–104. doi:10.1089/end.1996.10.93

10. Cai PY, Lee RS. "Ureteropelvic junction obstruction / hydronephrosis." Urol Clin North Am. 2023;50(3):361–369. doi:10.1016/j.ucl.2023.04.001

11. Kohno M, Ogawa T, Kojima Y, et al. "Pediatric congenital hydronephrosis (ureteropelvic junction obstruction): medical management guide." Int J Urol. 2020;27(5):369–376. doi:10.1111/iju.14207

12. Gurbuz C, Best SL, Donnally C, et al. "Intermediate term outcomes associated with the surveillance of ureteropelvic junction obstruction in adults." J Urol. 2011;185(3):926–929. doi:10.1016/j.juro.2010.10.082

13. Autorino R, Eden C, El-Ghoneimi A, et al. "Robot-assisted and laparoscopic repair of ureteropelvic junction obstruction: a systematic review and meta-analysis." Eur Urol. 2014;65(2):430–452. doi:10.1016/j.eururo.2013.06.053

14. Rassweiler JJ, Subotic S, Feist-Schwenk M, et al. "Minimally invasive treatment of ureteropelvic junction obstruction: long-term experience with an algorithm for laser endopyelotomy and laparoscopic retroperitoneal pyeloplasty." J Urol. 2007;177(3):1000–1005. doi:10.1016/j.juro.2006.10.049

15. Li P, Ma Y, Jin X, et al. "Comparative efficacy and safety of different minimal invasive pyeloplasty in treating patients with ureteropelvic junction obstruction: a network meta-analysis." World J Urol. 2023;41(10):2659–2669. doi:10.1007/s00345-023-04559-w

16. Hopf HL, Bahler CD, Sundaram CP. "Long-term outcomes of robot-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction." Urology. 2016;90:106–110. doi:10.1016/j.urology.2015.12.050

17. Yanke BV, Lallas CD, Pagnani C, McGinnis DE, Bagley DH. "The minimally invasive treatment of ureteropelvic junction obstruction: a review of our experience during the last decade." J Urol. 2008;180(4):1397–1402. doi:10.1016/j.juro.2008.06.020

18. Jacobs BL, Lai JC, Seelam R, et al. "The comparative effectiveness of treatments for ureteropelvic junction obstruction." Urology. 2018;111:72–77. doi:10.1016/j.urology.2017.09.002

19. O'Reilly PH. "Functional outcome of pyeloplasty for ureteropelvic junction obstruction: prospective study in 30 consecutive cases." J Urol. 1989;142(2 Pt 1):273–276.